99 related articles for article (PubMed ID: 16011043)
21. Increased serum prolactin pituitary reserve in patients with prostatic neoplasms.
Giuliani L; Pescatore D; Martorana G; Giberti C; Barreca T; Rolandi E
Br J Urol; 1979 Oct; 51(5):390-2. PubMed ID: 93008
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW
Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
[TBL] [Abstract][Full Text] [Related]
23. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.
Xu X; Kreye E; Kuo CB; Walker AM
Cancer Res; 2001 Aug; 61(16):6098-104. PubMed ID: 11507059
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia.
Lissoni P; Mandalà M; Giani L; Malugani F; Secondino S; Zonato S; Rocco F; Gardani G
Neuro Endocrinol Lett; 2000; 21(5):405-408. PubMed ID: 11452236
[TBL] [Abstract][Full Text] [Related]
25. Effects of radical mastectomy on prolactin blood levels in patients with breast cancer.
Barni S; Lissoni P; Paolorossi F; Crispino S; Rovelli F; Ferri L; Sormani A; D'Alonso U; Bugatti A; Nociti V
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1141-5. PubMed ID: 3653210
[TBL] [Abstract][Full Text] [Related]
26. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
27. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A
J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569
[TBL] [Abstract][Full Text] [Related]
28. Serum prolactin assays have no prognostic value in treatment of prostatic cancer by orchidectomy or estrogens.
Stege R; Carlström K; Eriksson A; Gustafsson SA; Henriksson P; Pousette A
Urol Int; 1987; 42(2):124-6. PubMed ID: 3617239
[TBL] [Abstract][Full Text] [Related]
29. A new PTP parameter as potential predictor of prostate cancer response to therapy.
Tarle M
Int J Rad Appl Instrum B; 1988; 15(2):225-7. PubMed ID: 3366623
[TBL] [Abstract][Full Text] [Related]
30. A study of surgical psychoncology in breast cancer: perioperative variation of prolactin serum levels in women with operable breast cancer in relation to their maternal psychological behaviour.
Messina G; Lissoni P; Brivio F; Rovelli F; Fumagalli L; Bartolacelli E; Mazza U; Colombo E; Bertoglio A
In Vivo; 2008; 22(6):845-8. PubMed ID: 19181018
[TBL] [Abstract][Full Text] [Related]
31. Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Caponnetto S; Iannantuono GM; Barchiesi G; Magri V; Gelibter A; Cortesi E
Oncology; 2017; 93(1):62-66. PubMed ID: 28407622
[TBL] [Abstract][Full Text] [Related]
32. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
[TBL] [Abstract][Full Text] [Related]
33. Does elevated morning prolactin concentration in children always mean the diagnosis of hyperprolactinemia?
Stawerska R; Smyczyńska J; Hilczer M; Lewiński A
Exp Clin Endocrinol Diabetes; 2015 Jul; 123(7):405-10. PubMed ID: 26069077
[TBL] [Abstract][Full Text] [Related]
34. Hyperprolactinemia due to big big prolactin is differently detected by commercially available immunoassays.
Cavaco B; Prazeres S; Santos MA; Sobrinho LG; Leite V
J Endocrinol Invest; 1999 Mar; 22(3):203-8. PubMed ID: 10219888
[TBL] [Abstract][Full Text] [Related]
35. Divergent neuroendocrine differentiation in prostatic carcinoma.
di Sant' Agnese PA
Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
[TBL] [Abstract][Full Text] [Related]
36. New concepts in prolactin biology.
Bernichtein S; Touraine P; Goffin V
J Endocrinol; 2010 Jul; 206(1):1-11. PubMed ID: 20371569
[TBL] [Abstract][Full Text] [Related]
37. Gastrin-releasing peptide: predictor of castration-resistant prostate cancer?
Heinrich E; Probst K; Michel MS; Trojan L
Prostate; 2011 May; 71(6):642-8. PubMed ID: 20945407
[TBL] [Abstract][Full Text] [Related]
38. Prolactin serum level in patients with breast cancer.
Cohen AD; Cohen Y; Maislos M; Buskila D
Isr Med Assoc J; 2000 Apr; 2(4):287-9. PubMed ID: 10804904
[TBL] [Abstract][Full Text] [Related]
39. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
[TBL] [Abstract][Full Text] [Related]
40. Altered diurnal rhythm of prolactin in systemic sclerosis.
Hilty C; Brühlmann P; Sprott H; Gay RE; Michel BA; Gay S; Neidhart M
J Rheumatol; 2000 Sep; 27(9):2160-5. PubMed ID: 10990228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
